TWEAK as a target for therapy in systemic lupus erythematosus

Molecular Biology Reports

Volumn 38, Issue 1, 2011, Pages 587-592

  Leng, Rui Xue ^a   Pan, Hai Feng ^a   Qin, Wei Zi ^a   Wang, Chao ^a   Chen, Li Li ^a   Tao, Jin Hui ^a   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Fn14; Systemic lupus erythematosus; TWEAK

Indexed keywords

CYTOKINE RECEPTOR; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PROTEIN TNFRSF12A; RANTES; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CYTOKINE PRODUCTION; GENE ACTIVATION; GENETIC ASSOCIATION; HUMAN; MESANGIUM CELL; MONOCYTE; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTORS;

EID: 78651089144     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0144-9     Document Type: Article

References (66)

1. D Foster J Parrish-Novak B Fox, et al. 2004 Cytokine-receptor pairing: accelerating discovery of cytokine function Nat Rev Drug Discov 3 160 170 1:CAS:528:DC%2BD2cXhtlaqs7w%3D 10.1038/nrd1305 15040579
2. JA Winkles 2008 The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting Nat Rev Drug Discov 7 411 425 1:CAS:528: DC%2BD1cXlt1agtb0%3D 10.1038/nrd2488 18404150 (Pubitemid 351619113)
3. RL Meighan-Mantha DK Hsu Y Guo, et al. 1999 The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration J Biol Chem 274 33166 33176 1:CAS:528:DyaK1MXntlynsrk%3D 10.1074/jbc.274.46.33166 10551889
4. SL Feng Y Guo VM Factor, et al. 2000 The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas Am J Pathol 156 1253 1261 1:CAS:528: DC%2BD3cXjtV2isbc%3D 10751351
5. A Ortiz AB Sanz B Muñoz García, et al. 2009 Considering TWEAK as a target for therapy in renal and vascular injury Cytokine Growth Factor Rev 20 251 258 1:CAS:528:DC%2BD1MXnsFaitLk%3D 10.1016/j.cytogfr.2009.05. 002 19482507
6. M Yepes 2007 TWEAK and the central nervous system Mol Neurobiol 35 255 265 1:CAS:528:DC%2BD2sXht1aisbvP 10.1007/s12035-007-0024-z 17917114 (Pubitemid 350129687)
7. M Yepes 2007 Tweak and FN14 in central nervous system health and disease Front Biosci 12 2772 2781 1:CAS:528:DC%2BD2sXms1Kmsrw%3D 10.2741/2271 17485258
8. N Schwartz T Rubinstein LC Burkly, et al. 2009 Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study Arthritis Res Ther 28 11 R143 10.1186/ar2816
9. A Molano P Lakhani A Aran, et al. 2009 TWEAK stimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis Immunol Lett 125 119 128 1:CAS:528:DC%2BD1MXps1WksLY%3D 10.1016/j.imlet.2009.06. 010 19573558
10. K Yanaba A Yoshizaki E Muroi, et al. 2009 Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis J Rheumatol 36 1657 1662 1:CAS:528:DC%2BD1MXhtV2hu7jE 10.3899/jrheum.081310 19531747
11. HX Gao SR Campbell LC Burkly, et al. 2009 TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells Cytokine 46 24 35 1:CAS:528:DC%2BD1MXjvVyjtr4%3D 10.1016/j.cyto.2008.12. 001 19233685
12. Z Zhao LC Burkly S Campbell, et al. 2007 TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus J Immunol 179 7949 7958 1:CAS:528:DC%2BD2sXhtlajt7bI 18025243
13. N Schwartz L Su LC Burkly, et al. 2006 Urinary TWEAK and the activity of lupus nephritis J Autoimmun 27 242 250 1:CAS:528:DC%2BD2sXhs1ChtLY%3D 10.1016/j.jaut.2006.12.003 17257812 (Pubitemid 46206104)
14. MJ Kaplan EE Lewis EA Shelden, et al. 2002 The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells J Immunol 169 6020 6029 1:CAS:528:DC%2BD38Xosl2isLw%3D 12421989
15. SR Wiley JA Winkles 2003 TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor Cytokine Growth Factor Rev 14 241 249 1:CAS:528:DC%2BD3sXkt1Ghsrk%3D 10.1016/S1359-6101(03) 00019-4 12787562 (Pubitemid 36693144)
16. S Campbell J Michaelson L Burkly, et al. 2004 The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity Front Biosci 9 2273 2284 1:CAS:528:DC%2BD2cXltl2nurs%3D 10.2741/1395 15353286
17. SR Wiley L Cassiano T Lofton, et al. 2001 A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis Immunity 15 837 846 1:CAS:528:DC%2BD3MXptVGgtbY%3D 10.1016/S1074-7613(01)00232-1 11728344 (Pubitemid 34008510)
18. SA Brown CM Richards HN Hanscom, et al. 2003 The Fn14 cytoplasmatic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappa B activation Biochem J 371 395 403 1:CAS:528:DC%2BD3sXisleqsr4%3D 10.1042/BJ20021730 12529173 (Pubitemid 36547622)
19. NL Tran WS McDonough BA Savitch, et al. 2005 The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NF-kappaB pathway activation and BCLXL/BCL-W expression J Biol Chem 280 3483 3492 1:CAS:528:DC%2BD2MXovVGiuw%3D%3D 10.1074/jbc.M409906200 15611130 (Pubitemid 40223813)
20. JA Winkles NL Tran ME Berens 2005 TWEAK and Fn14: new molecular targets for cancer therapy? Cancer Lett 235 11 17 10.1016/j.canlet.2005.03.048
21. T Saitoh M Nakayama H Nakano, et al. 2003 TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation J Biol Chem 278 36005 36012 1:CAS:528:DC%2BD3sXnt1aqtbs%3D 10.1074/jbc.M304266200 12840022 (Pubitemid 37139919)
22. Y Chicheportiche PR Bourdon H Xu, et al. 1997 TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis J Biol Chem 272 32401 32410 1:CAS:528:DyaK1cXis1Ojug%3D%3D 10.1074/jbc.272.51.32401 9405449 (Pubitemid 28011923)
23. SA Marsters JP Sheridan Rm Pitti, et al. 1998 Identification of a ligand for the death-domain containing receptor Apo3 Curr Biol 8 525 528 1:CAS:528:DyaK1cXislaksbg%3D 10.1016/S0960-9822(98)70204-0 9560343
24. TS Zheng LC Burkly 2008 No end in site: TWEAK/Fn14 activation and autoimmunity associated end-organ pathologies J Leukoc Biol 84 338 347 1:CAS:528:DC%2BD1cXptF2htrw%3D 10.1189/jlb.0308165 18483204
25. K Tanabe I Bonilla JA Winkles, et al. 2003 Fibroblast growth factor inducible-14 is induced in axotomized neurons and promotes neurite outgrowth J Neurosci 23 9675 9686 1:CAS:528:DC%2BD3sXoslKltrg%3D 14573547
26. P Justo AB Sanz MD Sanchez-Niño, et al. 2006 Cytokine cooperation in renal tubular cell injury: the role of TWEAK Kidney Int 70 1750 1758 1:CAS:528:DC%2BD28XhtFKitrjM 10.1038/sj.ki.5001866 17003819 (Pubitemid 44684806)
27. B Muñoz-Garcia JL Martin-Ventura E Martinez, et al. 2006 Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques modulation by atorvastatin Stroke 37 2044 2053 10.1161/01.STR.0000230648.00027.00 (Pubitemid 44309902)
28. AB Sanz P Justo MD Sanchez-Niño, et al. 2008 The cytokine TWEAK modulates renal tubulointerstitial inflammation J Am Soc Nephrol 19 695 703 1:CAS:528:DC%2BD1cXkvFOhsL0%3D 10.1681/ASN.2007050577 18235096
29. J Inoue T Ishida N Tsukamoto, et al. 2000 Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling Exp Cell Res 254 14 24 1:CAS:528:DC%2BD3cXht1Chtg%3D%3D 10.1006/excr.1999.4733 10623461 (Pubitemid 30066727)
30. SM Korbet EJ Lewis MM Schwartz 2000 Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group Am J Kidney Dis 5 904 914 10.1016/S0272-6386(00)70262-9
31. C Bossen K Ingold A Tardivel, et al. 2006 Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human J Biol Chem 281 13964 13971 1:CAS:528:DC%2BD28XksFeisr0%3D 10.1074/jbc.M601553200 16547002 (Pubitemid 43848322)
32. N Harada M Nakayama H Nakano, et al. 2002 Proinflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells Biochem Biophys Res Commun 299 488 493 1:CAS:528:DC%2BD38XoslGmsLs%3D 10.1016/S0006-291X(02) 02670-0 12445828 (Pubitemid 35365656)
33. M Nakayama K Ishidoh Y Kojima, et al. 2003 Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK induced cell death J Immunol 170 341 348 1:CAS:528:DC%2BD3sXhtFKjsw%3D%3D 12496418
34. LC Bover M Cardo-Vila A Kuniyasu, et al. 2007 A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications J Immunol 178 8183 8194 1:CAS:528:DC%2BD2sXmtVKntr8%3D 17548657
35. M Nakayama N Kayagaki N Yamaguchi, et al. 2000 Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity J Exp Med 192 1373 1380 1:CAS:528:DC%2BD3cXnvFWgtLo%3D 10.1084/jem.192.9.1373 11067885
36. AB Sanz B Santamaria M Ruiz Ortega, et al. 2008 Mechanisms of renal apoptosis in health and disease J Am Soc Nephrol 19 1634 1642 1:CAS:528:DC%2BD1cXhtFensr3K 10.1681/ASN.2007121336 18632846
37. G Valesini C Alessandri D Celestino, et al. 2006 Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus Ann NY Acad Sci 1069 118 128 1:CAS:528:DC%2BD28XovF2gs70%3D 10.1196/annals.1351.010 16855139 (Pubitemid 43989855)
38. American College of Rheumatology Ad Hoc Committee on Neuropsychiatric Lupus Syndromes 1999 The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes Arthritis Rheum 42 599 608 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F (Pubitemid 29171979)
39. JG Hanly G McCurdy L Fougere, et al. 2004 Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance J Rheumatol 31 2156 2162 15517627
40. I Potrovita W Zhang L Burkly, et al. 2004 Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration J Neurosci 24 8237 8244 1:CAS:528:DC%2BD2cXotVynt7g%3D 10.1523/JNEUROSCI.1089-04.2004 15385607 (Pubitemid 39280803)
41. M Yepes SA Brown EG Moore, et al. 2005 A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia Am J Pathol 166 511 520 1:CAS:528:DC%2BD2MXitVGmsrk%3D 15681834
42. X Zhang JA Winkles MC Gongora, et al. 2006 TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia J Cereb Blood Flow Metab 27 534 544 10.1038/sj.jcbfm.9600368 16835630
43. R Polavarapu MC Gongora JA Winkles, et al. 2005 Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor kappaB pathway activation J Neurosci 25 10094 10100 1:CAS:528:DC%2BD2MXht1WqtrfJ 10.1523/JNEUROSCI.3382-05.2005 16267216 (Pubitemid 41636205)
44. P Saas J Boucraut PR Walker, et al. 2000 TWEAK stimulation of astrocytes and the proinflammatory consequences Glia 32 102 107 1:STN:280: DC%2BD3M%2FivVGmtQ%3D%3D 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3. 0.CO;2-U 10975915
45. S Desplat-Jego S Varriale R Creidy, et al. 2002 TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity J Neuroimmunol 133 116 123 1:CAS:528:DC%2BD38Xoslant7g%3D 10.1016/S0165-5728(02) 00368-5 12446014 (Pubitemid 35346733)
46. S Desplat-Jego R Creidy S Varriale, et al. 2005 Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis Clin Immunol 117 15 23 1:CAS:528:DC%2BD2MXpslyns7w%3D 10.1016/j.clim.2005.06.005 16027043 (Pubitemid 41725465)
47. EJ Goetzl MJ Banda D Leppert 1996 Matrix metalloproteinases in immunity J Immunol 156 1 4 1:CAS:528:DyaK28XlsVCq 8598448
48. M Ram Y Sherer Y Shoenfeld 2006 Matrix metalloproteinase-9 and autoimmune diseases J Clin Immunol 26 299 307 1:CAS:528:DC%2BD28XmvVaqtrg%3D 10.1007/s10875-006-9022-6 16652230 (Pubitemid 44051377)
49. E Trysberg K Blennow O Zachrisson, et al. 2004 Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement Arthritis Res Ther 6 R551 R556 1:CAS:528:DC%2BD2cXpt1ajsb0%3D 10.1186/ar1228 15535833
50. M Bond RP Fabunmi AH Baker, et al. 1998 Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B FEBS Lett 435 29 34 1:CAS:528:DyaK1cXmtlSitLk%3D 10.1016/S0014-5793(98)01034-5 9755853 (Pubitemid 28432009)
51. SH Kim YJ Kang WJ Kim, et al. 2004 TWEAK can induce proinflammatory cytokines and matrix metalloproteinase-9 in macrophages Circ J 68 396 399 1:CAS:528:DC%2BD2cXjsVGgsbw%3D 10.1253/circj.68.396 15056843 (Pubitemid 38470720)
52. MB Urowitz AA Bookman BE Koehler, et al. 1976 The bimodal mortality pattern of systemic lupus erythematosus Am J Med 60 221 225 1:STN:280: DyaE287jtlyntQ%3D%3D 10.1016/0002-9343(76)90431-9 1251849
53. Y Asanuma A Oeser AK Shintani, et al. 2003 Premature coronary-artery atherosclerosis in systemic lupus erythematosus N Engl J Med 349 2407 2415 1:CAS:528:DC%2BD3sXpvFGqtbw%3D 10.1056/NEJMoa035611 14681506 (Pubitemid 37542989)
54. MJ Roman BA Shanker A Davis, et al. 2003 Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus N Engl J Med 349 2399 2406 1:CAS:528:DC%2BD3sXpvFGqtLo%3D 10.1056/NEJMoa035471 14681505 (Pubitemid 37542988)
55. JM Esdaile M Abrahamowicz T Grodzicky, et al. 2001 Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus Arthritis Rheum 44 2331 2337 1:STN:280: DC%2BD3MrmsVOjsg%3D%3D 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3. 0.CO;2-I 11665973 (Pubitemid 32977500)
56. CP Chung A Oeser I Avalos, et al. 2006 Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus Lupus 15 562 569 1:STN:280:DC%2BD28nkslChug%3D%3D 10.1177/0961203306071870 17080910 (Pubitemid 44661742)
57. YH Rho CP Chung A Oeser, et al. 2008 Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus J Rheumatol 35 Sept 1789 1794 1:CAS:528:DC%2BD1cXhtFyqtbvK 18634156
58. LM Blanco-Colio JL Martín-Ventura B Munoz-Garcia, et al. 2007 TWEAK and Fn14. New players in the pathogenesis of atherosclerosis Front Biosci 12 3648 3655 1:CAS:528:DC%2BD2sXms1KmtbY%3D 10.2741/2341 17485328
59. T Henkel T Machleidt I Alkalay, et al. 1993 Rapid proteolysis of IkB-a is necessary for activation of transcription factor NF-kB Nature 365 182 185 1:CAS:528:DyaK3sXms1equ74%3D 10.1038/365182a0 8371761 (Pubitemid 23282067)
60. D Fukuda K Shimada A Tanaka, et al. 2006 Comparison of levels of serum matrix metalloproteinase-9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris Am J Cardiol 97 175 180 1:CAS:528:DC%2BD28Xos1Wiug%3D%3D 10.1016/j.amjcard.2005.08.020 16442358 (Pubitemid 43139231)
61. X Jiang HS Zeng Y Guo, et al. 2004 The expression of matrix metalloproteinases-9, transforming growth factor-beta1 and transforming growth factor-beta receptor I in human atherosclerotic plaque and their relationship with plaque stability Chin Med J (Engl) 117 1825 1829 1:CAS:528: DC%2BD2MXhtVOntb8%3D
62. S Campbell LC Burkly HX Gao, et al. 2006 Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells J Immunol 176 1889 1898 1:CAS:528:DC%2BD28XlsFyktg%3D%3D 16424220
63. JA Moreno B Muñoz-García JL Martín-Ventura, et al. 2009 The CD163-expressing macrophages recognize and internalize TWEAK potential consequences in atherosclerosis Atherosclerosis 207 103 110 1:CAS:528: DC%2BD1MXhtlyrtbnL 10.1016/j.atherosclerosis.2009.04.033 19473660
64. XF Zhao HF Pan H Yuan, et al. 2010 Increased serum interleukin 17 in patients with systemic lupus erythematosus Mol Biol Rep 37 81 85 10.1007/s11033-009-9533-3 19347604
65. HF Pan GC Wu WP Li, et al. 2010 High mobility group box 1: a potential therapeutic target for systemic lupus erythematosus Mol Biol Rep 37 1191 1195 1:CAS:528:DC%2BC3cXhtlajurw%3D 10.1007/s11033-009-9485-7 19247800
66. HF Pan N Zhang WX Li, et al. 2010 TIM-3 as a new therapeutic target in systemic lupus erythematosus Mol Biol Rep 37 395 398 1:CAS:528: DC%2BC3cXisFSmtw%3D%3D 10.1007/s11033-009-9833-7 19768575